Roche signed up Dualitas Therapeutics to run a broad bispecific screening effort using Dualitas’ Dualscreen engine, with deal economics reaching up to $1 billion. Dualitas will screen more than 300,000 tethered bispecific combinations for synergistic immunology and inflammation effects compared with individual antibodies, receiving $36.5 million upfront and additional milestone payments plus royalties.